Clinical Trial Update: Effects of Tinzaparin on Cardio-vascular Outcomes and on Blood Lipids in Diabetic Patients on Chronic Hemodialysis [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating tinzaparin for cardiovascular outcomes and lipid effects in diabetic patients undergoing chronic hemodialysis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Diabetes Mellitus
• Hemodialysis

Drugs mentioned

• tinzaparin (tinzaparin)

Snippet

Sponsor: Anemia Working Group Romania | Conditions: Diabetes Mellitus, Hemodialysis | Phase 4 | Status: WITHDRAWN